- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Marvel Biosciences Corp: Marvel Biosciences amends debenture conversion price | 1 | Stockwatch | ||
| Mo | Marvel Biosciences lowers conversion price for proposed debenture offering | 1 | Seeking Alpha | ||
| Mo | Marvel Biosciences Corp.: Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering | 362 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") Further to the Company's press release of April 8, 2026, announcing its intention... ► Artikel lesen | |
| MARVEL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 08.04. | Marvel Biosciences plans convertible debenture private placement | 3 | Seeking Alpha | ||
| 08.04. | Marvel Biosciences Corp.: Marvel Biosciences Announces Proposed Convertible Debenture Offering | 372 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 8, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement... ► Artikel lesen | |
| 07.04. | Marvel Biosciences Corp: Marvel Biosciences gets backing from 5 Horizons | 5 | Stockwatch | ||
| 07.04. | Marvel Biosciences Corp.: Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures | 315 | GlobeNewswire (Europe) | CALGARY, Alberta, April 07, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company")... ► Artikel lesen | |
| 30.03. | Marvel Biosciences Corp: Marvel obtains Alberta funding for MB-204 phase I | 1 | Stockwatch | ||
| 30.03. | Marvel Biosciences Corp.: Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204 | 1 | GlobeNewswire (USA) | ||
| 25.03. | Marvel Biosciences Corp: Marvel Biosciences selects Novotech for MB-204 trial | 1 | Stockwatch | ||
| 25.03. | Marvel Biosciences Corp.: Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204 | 356 | GlobeNewswire (Europe) | CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company")... ► Artikel lesen | |
| 18.03. | Marvel Biosciences Corp: Marvel Biosciences obtains U.S. patent for drug MB-204 | 1 | Stockwatch | ||
| 18.03. | Marvel Biosciences Corp.: Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204 | 209 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the... ► Artikel lesen | |
| 04.03. | Marvel Biosciences Corp.: Marvel Biosciences Sponsors Scientific Meeting on Purines | 208 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 4, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the... ► Artikel lesen | |
| 19.02. | Marvel Biosciences Corp: Marvel Biosciences obtains financing to develop drug | 2 | Stockwatch | ||
| 18.02. | Marvel Biosciences Corp.: Marvel Biosciences Announces Grant of Deferred Share Units | 393 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel")... ► Artikel lesen | |
| 18.02. | Marvel Biosciences Corp.: Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders | 152 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), is pleased to announce that it is receiving advisory services and funding from the... ► Artikel lesen | |
| 04.02. | Marvel Biosciences Corp: Marvel Biosciences receives Japanese patent for MB-204 | 1 | Stockwatch | ||
| 03.02. | Marvel Biosciences Corp.: Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204 | 347 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or... ► Artikel lesen | |
| 22.12.25 | Toronto Stock Exchange: Toronto Stock Exchange, Marvel Biosciences Corp., The View from the C-Suite | 421 | Newsfile | Toronto, Ontario--(Newsfile Corp. - December 22, 2025) - Rod Matheson, Chief Executive Officer, and Mark Williams, Chief Strategy Officer, from Marvel Biosciences Corp. (the "Company") (TSXV: MRVL)... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,915 | +1,60 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| IMMUNOVANT | 26,550 | +5,65 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,850 | +4,17 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| PRAXIS PRECISION MEDICINES | 343,21 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,050 | 0,00 % | Vir Biotechnology startet Erweiterungsstudie für Prostatakrebs-Wirkstoff VIR-5500 | ||
| ARCUTIS BIOTHERAPEUTICS | 25,090 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth | WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 44,850 | 0,00 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| EVOTEC | 5,390 | +14,68 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das vierte Quartal und Gesamtjahr 2025 bekannt: Grundlage für profitables Wachstum | EQS-News: Evotec SE
/ Schlagwort(e): Jahresergebnis
Evotec gibt Ergebnisse für das vierte Quartal und Gesamtjahr 2025 bekannt: Grundlage für profitables Wachstum
08.04.2026... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,280 | 0,00 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,300 | +2,45 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,540 | 0,00 % | Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform | NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 14,350 | +0,70 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended... ► Artikel lesen | |
| TREVI THERAPEUTICS | 14,040 | +5,25 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 9,660 | -3,88 % | 4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones | Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data... ► Artikel lesen | |
| CG ONCOLOGY | 67,26 | 0,00 % | CG Oncology, Inc. - 8-K, Current Report |
Das Unternehmen MARVEL BIOSCIENCES CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MARVEL BIOSCIENCES CORP finden Sie auf Wallstreet Online.